58 Investor presentation First three months of 2021 In STEP 1, people treated with se weight loss of up to 16.9% The pivotal STEP 1 trial showed greater than 16% weight loss % change in body weight 0 -2 Placebo: -2.4% -4 -6 -8 -10 -12 -14 -16 -18 Semaglutide: -16.9% -20 0 4 8 12 16 20 28 36 44 52 60 68 Time since initiation (weeks) Change in body weight in % depicts observed means since time of randomisation; trial product estimand. BMI: body mass index; SF-36: Short Form (36) Health Survey; IWQoL-lite-CT: Impact of Weight on Quality of Life-Lite questionnaire
Download PDF file